Here’s a novel idea: Allergan should consider buying Valeant, according to one of the embattled drugmaker’s few cheerleaders. But Allergan isn’t so keen on that plan.
Value investor Bill Miller, who manages the Legg Mason Opportunity Trust, put the suggestion out there Tuesday at the Delivering Alpha conference in New York, The Wall Street Journal’s Dave Benoit tweeted.
Valeant, of course, tried for most of 2014 to buy Allergan before then-Actavis swooped in as a white knight. Since then, Valeant has unraveled, suffering through political pricing pushback, channel-stuffing allegations and debt-default worries–among other issues–to the point that it’s now looking to sell off pieces of its business to raise cash.
Several Wall Streeters were burned as Valeant spun out of control–including Bill Ackman of Pershing Square Capital Management, who teamed up with Valeant on the failed Allergan pursuit and earlier this year joined Valeant’s board in an effort to right the sinking ship.
Miller, though, sees the Canadian company as a money-making opportunity. He poured about 3.5% of his fund into Valeant in late March and early April, he said earlier this year, telling the WSJ that “where you want to take some risk is on companies that have already gotten crushed.”
Allergan chief Brent Saunders isn’t interested in any such risk.
“Every one of our acquisitions or deals has been growth-oriented. We look to buy young products that we think we can put into our hands and do better with and really grow, or we buy R&D assets. And best I can tell, Valeant just doesn’t fit that bill,” he said in an interview with CNBC last week.
Instead, Allergan is zeroing in on so-called “stepping stone” deals “where we can really add to the therapeutic presence and look for cures and treatments for unmet need,” he said–and the Dublin drugmaker has stayed true to that focus lately, last week agreeing to snap up gene therapy startup RetroSense to get its hands on a candidate for a rare vision disorder.
And Wednesday, the company announced another pact–this one a $639 million accord for Vitae Pharma that’ll boost its dermatology pipeline–without engaging with skincare-focused Valeant.
That doesn’t mean Valeant hasn’t seen any interest from other takers, though. It reportedly turned down a joint takeover effort from Takeda and TPG, sources told the WSJ in May. And other buyers, including Spain’s Almirall, have expressed interest in snatching up pieces of Valeant’s business.
“We’re still in very initial stages, but there are things that could interest us. We’re studying the situation but waiting for more information,” CEO Eduardo Sanchiz told Reuters in July.
By Carly Helfand
Source: Fierce Pharma
Novo Holdings has concluded the acquisition of all outstanding shares of commercial-stage biopharmaceutical company Paratek Pharmaceuticals for nearly $462m (€433.67m) to bolster its antimicrobial resistance (AMR) expertise. Paratek develops and commercialises new treatments for life-threatening ailments. Its speciality pharmaceutical platform aids in developing new therapeutics.
Glenmark Pharmaceuticals has signed a definitive agreement for the divestiture of a 75% stake in its division, Glenmark Life Sciences (GLS), to Indian company Nirma in a deal valued at Rs56.51bn ($679.85m). Glenmark Life Sciences focuses on producing active pharmaceutical ingredients (API).
Pierre-Alain Ruffieux, CEO of Lonza, will leave the Basel-based company at the end of September. According to the Swiss Contract Development and Manufacturing Organization (CDMO), the separation is by mutual agreement.